甘草酸苷制剂联合熊去氧胆酸治疗自身免疫性肝炎及原发性胆汁性肝硬化的临床观察  

Clinical observation on the safety and efficacy of ursodeoxycholic acid and glycyrrhizin in the treatment of primary biliary cirrhosis and autoimmune hepatitis

作　　者：刘震霞[1] 刘洋[1] 刘翠英[1] 

机构地区：[1]河北省保定市传染病医院,河北保定071000

出　　处：《中国医药导报》2011年第20期113-114,共2页China Medical Herald

摘　　要：目的:观察甘草酸苷制剂联合熊去氧胆酸治疗自身免疫性肝炎(AIH)及原发性胆汁性肝硬化(PBC)的疗效。方法:将原发性胆汁性肝硬化病例分为两组,治疗组应用甘草酸苷制剂联合熊去氧胆酸治疗,对照组应用熊去氧胆酸治疗,观察两组的疗效及不良反应,同时观察甘草酸苷制剂联合熊去氧胆酸对自身免疫性肝炎病例的疗效及不良反应。结果:PBC治疗组患者的ALT、AST、GGT水平较治疗前明显降低(P<0.05或P<0.01),但两组间疗效比较差异无统计学意义。应用UDCA和甘草酸苷联合治疗后,AIH患者的ALT、AST、GGT水平明显降低(P<0.05或P<0.01)。结论:对AIH和PBC患者应用熊去氧胆酸和甘草酸苷联合治疗安全有效。Objective：To assess efficacy and safety of ursodeoxycholic acid and glycyrrhizin in the treatment of primary biliary cirrhosis（PBC） and autoimmune hepatitis（AIH）.Methods：The patients of PBC were divided into two groups,the treatment group was given UDCA and glycyrrhizin,the control group was given UDCA.The patients of AIH was given UDCA and glycyrrhizin.The response to therapy of the patients with AIH and PBC were analyzed particularly.Results：In the treatment group of PBC the levels of ALT,AST and GGT dropped more rapidly（P0.05 or P0.01）.In efficacy there was no significance difference between the two groups（P0.05）.After combination therapy with ursodeoxycholic acid（UDCA） and glycyrrhizin,in AIH group the levels of ALT,AST and GGT decreased significantly（P0.05 or P0.01）.Conclusion：Combination therapy with UDCA and glycyrrhizin is effective and safe in patients with PBC and AIH.

关 键 词：甘草酸苷制剂 熊去氧胆酸 自身免疫性肝炎 原发性胆汁性肝硬化 治疗 

分 类 号：R575[医药卫生—消化系统]